Monopar Therapeutics Inc Financials

MNPR

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Monopar Therapeutics Inc (MNPR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MNPR FY2025 2026-05-14

FY2025 was shaped more by financing and balance-sheet repositioning than by operations, with equity-funded liquidity carrying a still-lossmaking research business.

Cash burn and accounting loss diverged in FY2025: operating cash outflow worsened by about $5.8M year over year even as net loss improved by roughly $1.9M. $91.6M of financing inflow still lifted year-end cash to $61.8M, showing that funding decisions and capital redeployment, rather than operating cash generation, determined how much capacity the business had.

The balance sheet is unusually lightly encumbered for a cash-burning company: liabilities were just $2.9M against equity of $137.8M. That makes this look less like a debt-supported operating business and more like an equity-financed development platform whose main constraint is how quickly spending consumes capital.

Expense mix shifted rather than simply expanding: R&D fell to $9.9M from $13.0M. Yet operating loss stayed near prior-year levels because SG&A absorbed much of that relief, which means overhead became a larger part of the cost base even as direct program spend eased.

Financial Health Signals

Financial health score pending refresh

We are recalculating Monopar Therapeutics Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Altman Z-Score Safe

138.67

Monopar Therapeutics Inc scores 138.67, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($668.5M) relative to total liabilities ($2.9M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/7

Monopar Therapeutics Inc passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.89x

For every $1 of reported earnings, Monopar Therapeutics Inc generates $0.89 in operating cash flow (-$12.2M OCF vs -$13.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Monopar Therapeutics Inc generated $0 in revenue in fiscal year 2025.

EBITDA

N/A

Net Income

-$13.7M

YoY+12.0%

Monopar Therapeutics Inc reported -$13.7M in net income in fiscal year 2025. This represents an increase of 12.0% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$61.8M

YoY+35.0%

5Y CAGR+29.9%

Monopar Therapeutics Inc held $61.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+9.7%

Monopar Therapeutics Inc had 7M shares outstanding in fiscal year 2025. This represents an increase of 9.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-10.0%

YoY+18.4pp

5Y CAGR+30.2pp

Monopar Therapeutics Inc's ROE was -10.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 18.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$9.9M

YoY-23.8%

5Y CAGR+19.5%

Monopar Therapeutics Inc invested $9.9M in research and development in fiscal year 2025. This represents a decrease of 23.8% from the prior year.

Share Buybacks

$35.0M

Monopar Therapeutics Inc spent $35.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

N/A

MNPR Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$0	$0	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$9.9M-23.8%	$13.0M+132.2%	$5.6M-26.2%	$7.6M+16.9%	$6.5M+59.7%	$4.1M
SG&A Expenses	$6.8M+115.5%	$3.2M-2.3%	$3.2M+9.7%	$2.9M+11.8%	$2.6M+7.8%	$2.4M
Operating Income	-$16.7M-3.4%	-$16.2M-83.0%	-$8.8M+16.2%	-$10.5M-15.4%	-$9.1M-40.2%	-$6.5M
Interest Expense	N/A	N/A	$429K+1920.1%	$21K-11.6%	$24K-70.7%	$82K
Income Tax	$8000.0%	$8000.0%	$8000.0%	$800	$0-100.0%	$18K
Net Income	-$13.7M+12.0%	-$15.6M-85.5%	-$8.4M+20.1%	-$10.5M-15.5%	-$9.1M-44.4%	-$6.3M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$3.5M	N/A	$2.6M+49.7%	$1.7M+5.3%	$1.6M	N/A	$984K-13.0%	$1.1M
SG&A Expenses	$1.7M	N/A	$1.5M-0.1%	$1.5M-4.7%	$1.6M	N/A	$591K-10.2%	$658K
Operating Income	-$5.2M	N/A	-$4.1M-26.6%	-$3.2M-0.4%	-$3.2M	N/A	-$1.6M+12.0%	-$1.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$73K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.9M	N/A	-$3.4M-40.1%	-$2.5M+6.5%	-$2.6M	N/A	-$1.3M+24.0%	-$1.7M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

MNPR Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$140.7M+133.4%	$60.3M+720.8%	$7.3M-44.5%	$13.2M-35.5%	$20.5M+21.7%	$16.9M
Current Assets	$140.5M+133.0%	$60.3M+722.2%	$7.3M-44.3%	$13.2M-35.8%	$20.5M+22.2%	$16.8M
Cash & Equivalents	$61.8M+35.0%	$45.8M+530.6%	$7.3M-11.2%	$8.2M-59.7%	$20.3M+21.3%	$16.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.9M-45.0%	$5.3M+199.0%	$1.8M-44.0%	$3.1M+98.5%	$1.6M+34.3%	$1.2M
Current Liabilities	$2.7M-47.9%	$5.3M+199.0%	$1.8M-43.8%	$3.1M+98.0%	$1.6M+34.3%	$1.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$137.8M+150.4%	$55.0M+885.0%	$5.6M-44.6%	$10.1M-46.7%	$18.9M+20.7%	$15.7M
Retained Earnings	-$89.5M-18.1%	-$75.8M-25.9%	-$60.2M-16.2%	-$51.8M-25.5%	-$41.3M-28.3%	-$32.2M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$138.0M-1.9%	$140.7M-2.4%	$144.2M+167.7%	$53.9M-2.2%	$55.1M-8.6%	$60.3M+893.3%	$6.1M-15.5%	$7.2M
Current Assets	$137.7M-1.9%	$140.5M-2.5%	$144.1M+168.1%	$53.7M-2.4%	$55.1M-8.6%	$60.3M+893.3%	$6.1M-15.5%	$7.2M
Cash & Equivalents	$52.5M-15.0%	$61.8M-51.6%	$127.7M+223.2%	$39.5M-0.5%	$39.7M-13.3%	$45.8M+661.1%	$6.0M-1.6%	$6.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.6M-10.4%	$2.9M+9.5%	$2.6M+58.6%	$1.7M+11.5%	$1.5M-71.6%	$5.3M+367.9%	$1.1M+3.1%	$1.1M
Current Liabilities	$2.5M-10.1%	$2.7M+6.5%	$2.6M+62.2%	$1.6M	N/A	$5.3M	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$135.4M-1.8%	$137.8M-2.6%	$141.6M+171.2%	$52.2M-2.6%	$53.6M-2.6%	$55.0M+1012.6%	$4.9M-18.8%	$6.1M
Retained Earnings	-$93.4M-4.3%	-$89.5M-6.2%	-$84.3M-4.3%	-$80.9M-3.1%	-$78.4M-3.5%	-$75.8M-16.8%	-$64.9M-2.1%	-$63.6M

MNPR Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$12.2M-90.5%	-$6.4M+18.5%	-$7.9M-8.7%	-$7.2M+1.2%	-$7.3M-56.9%	-$4.7M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$63.5M-342.5%	-$14.3M-391.0%	$4.9M+200.2%	-$4.9M	$0	N/A
Financing Cash Flow	$91.6M+54.4%	$59.3M+2824.8%	$2.0M+6066.8%	$33K-99.7%	$10.9M+33.0%	$8.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$35.0M	$0	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$3.5M-3.1%	-$3.4M-61.2%	-$2.1M-94.0%	-$1.1M+81.0%	-$5.7M-183.4%	-$2.0M-86.2%	-$1.1M+36.0%	-$1.7M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$5.6M+91.0%	-$62.2M-2825.1%	-$2.1M-279.1%	$1.2M+464.4%	-$326K+97.7%	-$14.3M-1554.6%	$986K+40782.2%	-$2K
Financing Cash Flow	-$200K+48.0%	-$385K-100.4%	$92.4M+29259.9%	-$317K-173.9%	-$116K-100.2%	$56.1M+339623.6%	-$17K-66.7%	-$10K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$35.0M	$0	N/A	N/A	N/A	$0	N/A	N/A

MNPR Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-10.0%+18.4pp	-28.3%+122.0pp	-150.4%-46.1pp	-104.2%-56.2pp	-48.1%-7.9pp	-40.2%
Return on Assets	-9.8%+16.1pp	-25.9%+88.5pp	-114.4%-34.9pp	-79.5%-35.1pp	-44.4%-7.0pp	-37.4%
Current Ratio	51.35+39.9	11.47+7.3	4.17-0.0	4.21-8.8	12.98-1.3	14.28
Debt-to-Equity	0.02-0.1	0.10-0.2	0.310.0	0.31+0.2	0.080.0	0.07
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-2.9%	N/A	-2.4%+2.3pp	-4.7%+0.2pp	-4.9%	N/A	-26.4%+1.8pp	-28.2%
Return on Assets	-2.8%	N/A	-2.4%+2.2pp	-4.5%+0.2pp	-4.8%	N/A	-21.5%+2.4pp	-23.9%
Current Ratio	56.04+4.7	51.35-4.7	56.10+22.2	33.94	N/A	11.47	N/A	N/A
Debt-to-Equity	0.020.0	0.020.0	0.02-0.0	0.030.0	0.03-0.1	0.10-0.1	0.23+0.0	0.18
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Foghorn Therapeutics Inc. FHTX

$315.9M

Lineage Cell The LCTX

$304.1M

Alector ALEC

$154.3M

Annexon, Inc. ANNX

$909.3M

Lexeo Therapeutics Inc LXEO

$362.8M

Frequently Asked Questions

What is Monopar Therapeutics Inc's annual revenue?

Monopar Therapeutics Inc (MNPR) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Monopar Therapeutics Inc profitable?

No, Monopar Therapeutics Inc (MNPR) reported a net income of -$13.7M in fiscal year 2025.

What is Monopar Therapeutics Inc's return on equity (ROE)?

Monopar Therapeutics Inc (MNPR) has a return on equity of -10.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Monopar Therapeutics Inc's operating cash flow?

Monopar Therapeutics Inc (MNPR) generated -$12.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Monopar Therapeutics Inc's total assets?

Monopar Therapeutics Inc (MNPR) had $140.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Monopar Therapeutics Inc spend on research and development?

Monopar Therapeutics Inc (MNPR) invested $9.9M in research and development during fiscal year 2025.

Does Monopar Therapeutics Inc buy back shares?

Yes, Monopar Therapeutics Inc (MNPR) spent $35.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Monopar Therapeutics Inc have outstanding?

Monopar Therapeutics Inc (MNPR) had 7M shares outstanding as of fiscal year 2025.

What is Monopar Therapeutics Inc's current ratio?

Monopar Therapeutics Inc (MNPR) had a current ratio of 51.35 as of fiscal year 2025, which is generally considered healthy.

What is Monopar Therapeutics Inc's debt-to-equity ratio?

Monopar Therapeutics Inc (MNPR) had a debt-to-equity ratio of 0.02 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Monopar Therapeutics Inc's return on assets (ROA)?

Monopar Therapeutics Inc (MNPR) had a return on assets of -9.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Monopar Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Monopar Therapeutics Inc (MNPR) had $61.8M in cash against an annual operating cash burn of $12.2M. This gives an estimated cash runway of approximately 61 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Monopar Therapeutics Inc's Altman Z-Score?

Monopar Therapeutics Inc (MNPR) has an Altman Z-Score of 138.67, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Monopar Therapeutics Inc's Piotroski F-Score?

Monopar Therapeutics Inc (MNPR) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Monopar Therapeutics Inc's earnings high quality?

Monopar Therapeutics Inc (MNPR) has an earnings quality ratio of 0.89x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.